• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

病例报告：一例经过多次治疗的转移性三阴性乳腺癌患者对乐伐替尼与免疫检查点抑制剂联合治疗有显著反应

Case Report: Significant Response to the Combination of Lenvatinib and Immune Checkpoint Inhibitor in a Patient With Heavily Pretreated Metastatic Triple Negative Breast Cancer.

作者信息

Lee Jin Sun, Yost Susan E, Yuan Yuan

机构信息

Department of Medical Oncology & Molecular Therapeutics, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, United States.

出版信息

Front Oncol. 2021 Jan 11;10:582185. doi: 10.3389/fonc.2020.582185. eCollection 2020.

DOI:10.3389/fonc.2020.582185
PMID:33505906
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7830150/
Abstract

BACKGROUND

Triple negative breast cancer (TNBC) has poor prognosis without targetable mutations. The combination of lenvatinib and pembrolizumab has shown clinical activity in different types of solid tumors.

CASE PRESENTATION

We report a case of one patient with metastatic TNBC who has been heavily pretreated. The patient had been treated with multiple lines (≥ 8 lines) of chemotherapy without durable clinical responses. Her tumor regressed significantly under the combination of lenvatinib and immune checkpoint inhibitor, and remains stable for 10 months.

CONCLUSIONS

The combination of lenvatinib and immune checkpoint inhibitor may have significant clinical activity in selective patients with heavily pretreated metastatic TNBC.

摘要

背景

三阴性乳腺癌（TNBC）预后较差，且无可靶向的突变。乐伐替尼和帕博利珠单抗联合用药已在不同类型实体瘤中显示出临床活性。

病例报告

我们报告一例转移性TNBC患者，该患者此前接受过多种治疗。患者接受了多线（≥8线）化疗，但未获得持久的临床缓解。在乐伐替尼和免疫检查点抑制剂联合治疗下，她的肿瘤显著消退，并保持稳定达10个月。

结论

乐伐替尼和免疫检查点抑制剂联合用药可能对经过多线治疗的转移性TNBC患者具有显著临床活性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f3e/7830150/77122f2373aa/fonc-10-582185-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f3e/7830150/4eb1d7e55721/fonc-10-582185-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f3e/7830150/77122f2373aa/fonc-10-582185-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f3e/7830150/4eb1d7e55721/fonc-10-582185-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f3e/7830150/77122f2373aa/fonc-10-582185-g002.jpg

相似文献

1
Case Report: Significant Response to the Combination of Lenvatinib and Immune Checkpoint Inhibitor in a Patient With Heavily Pretreated Metastatic Triple Negative Breast Cancer.病例报告：一例经过多次治疗的转移性三阴性乳腺癌患者对乐伐替尼与免疫检查点抑制剂联合治疗有显著反应
Front Oncol. 2021 Jan 11;10:582185. doi: 10.3389/fonc.2020.582185. eCollection 2020.
2
Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 Study.乐伐替尼联合帕博利珠单抗治疗既往治疗的晚期三阴性乳腺癌患者：来自 2 期 LEAP-005 研究三阴性乳腺癌队列的结果。
Cancer. 2024 Oct 1;130(19):3278-3288. doi: 10.1002/cncr.35387. Epub 2024 Jun 21.
3
A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer.派姆单抗和恩博索姆治疗雄激素受体阳性转移性三阴性乳腺癌患者的 II 期临床试验。
Oncologist. 2021 Feb;26(2):99-e217. doi: 10.1002/onco.13583. Epub 2020 Nov 24.
4
Combination of pembrolizumab and lenvatinib is a potential treatment option for heavily pretreated recurrent and metastatic head and neck cancer.帕博利珠单抗联合仑伐替尼是一种潜在的治疗选择，用于治疗经大量预处理的复发性和转移性头颈部癌症。
J Chin Med Assoc. 2021 Apr 1;84(4):361-367. doi: 10.1097/JCMA.0000000000000497.
5
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.乐伐替尼联合帕博利珠单抗治疗未经治疗或既往治疗的转移性肾细胞癌患者（研究 111/KEYNOTE-146）：一项 Ib/II 期研究。
Lancet Oncol. 2021 Jul;22(7):946-958. doi: 10.1016/S1470-2045(21)00241-2. Epub 2021 Jun 15.
6
Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.三阴性乳腺癌免疫检查点阻断反应的生物标志物。
Curr Treat Options Oncol. 2021 Mar 20;22(5):38. doi: 10.1007/s11864-021-00833-4.
7
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer.TROPION-Breast05：一项随机III期研究，对比了在PD-L1高表达的局部复发不可切除或转移性三阴性乳腺癌患者中，使用或不使用度伐利尤单抗的德曲妥珠单抗（Dato-DXd）与化疗联合帕博利珠单抗的疗效。
Ther Adv Med Oncol. 2025 Apr 17;17:17588359251327992. doi: 10.1177/17588359251327992. eCollection 2025.
8
Durable Response to Programmed Death 1-Directed Antibodies in a Hypermutated Triple-Negative Breast Cancer: A Case Report.高突变三阴性乳腺癌对程序性死亡1导向抗体的持久反应：一例报告
Case Rep Oncol. 2024 Mar 1;17(1):392-398. doi: 10.1159/000535743. eCollection 2024 Jan-Dec.
9
Pilot clinical trial and phenotypic analysis in chemotherapy-pretreated, metastatic triple-negative breast cancer patients treated with oral TAK-228 and TAK-117 (PIKTOR) to increase DNA damage repair deficiency followed by cisplatin and nab paclitaxel.在接受口服TAK-228和TAK-117（PIKTOR）治疗以增加DNA损伤修复缺陷，随后接受顺铂和白蛋白结合型紫杉醇治疗的化疗预处理转移性三阴性乳腺癌患者中进行的先导性临床试验和表型分析。
Biomark Res. 2023 Jul 25;11(1):73. doi: 10.1186/s40364-023-00511-7.
10
Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer.帕博利珠单抗联合化疗用于晚期三阴性乳腺癌的一线治疗。
Future Oncol. 2024;20(22):1587-1600. doi: 10.2217/fon-2023-0301. Epub 2024 Apr 10.

引用本文的文献

1
Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment.三阴性乳腺癌治疗药物研发的最新进展。
Molecules. 2023 Nov 9;28(22):7513. doi: 10.3390/molecules28227513.
2
Synergistic Anti-Angiogenic Effect of Combined VEGFR Kinase Inhibitors, Lenvatinib, and Regorafenib: A Therapeutic Potential for Breast Cancer.联合 VEGFR 激酶抑制剂仑伐替尼和瑞戈非尼的协同抗血管生成作用：乳腺癌的治疗潜力。
Int J Mol Sci. 2022 Apr 16;23(8):4408. doi: 10.3390/ijms23084408.
3
TNBC: Potential Targeting of Multiple Receptors for a Therapeutic Breakthrough, Nanomedicine, and Immunotherapy.

本文引用的文献

1
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.IMpassion131 研究是一项双盲、安慰剂对照、随机 III 期临床试验，旨在评估一线紫杉醇联合或不联合阿替利珠单抗治疗不可切除局部晚期/转移性三阴性乳腺癌的主要结果。
Ann Oncol. 2021 Aug;32(8):994-1004. doi: 10.1016/j.annonc.2021.05.801. Epub 2021 Jul 1.
2
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.帕博利珠单抗联合化疗对比安慰剂联合化疗用于治疗既往未经治疗的局部晚期不可切除或转移性三阴性乳腺癌（KEYNOTE-355）：一项随机、安慰剂对照、双盲、III 期临床研究。
Lancet. 2020 Dec 5;396(10265):1817-1828. doi: 10.1016/S0140-6736(20)32531-9.
3
三阴性乳腺癌：针对多种受体实现治疗突破、纳米医学及免疫疗法的潜在靶点
Biomedicines. 2021 Jul 23;9(8):876. doi: 10.3390/biomedicines9080876.
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.仑伐替尼联合帕博利珠单抗治疗晚期子宫内膜癌患者。
J Clin Oncol. 2020 Sep 10;38(26):2981-2992. doi: 10.1200/JCO.19.02627. Epub 2020 Mar 13.
4
Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy.肿瘤微环境对免疫检查点治疗的致敏作用。
Front Immunol. 2020 Feb 18;11:223. doi: 10.3389/fimmu.2020.00223. eCollection 2020.
5
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.仑伐替尼联合帕博利珠单抗治疗晚期肾细胞癌、子宫内膜癌和其他选定的晚期实体瘤的 Ib/II 期临床试验。
J Clin Oncol. 2020 Apr 10;38(11):1154-1163. doi: 10.1200/JCO.19.01598. Epub 2020 Jan 21.
6
The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer.IV 期乳腺癌不同转移部位患者的临床病理特征和生存结局。
BMC Cancer. 2019 Nov 12;19(1):1091. doi: 10.1186/s12885-019-6311-z.
7
Lenvatinib promotes antitumor immunity by enhancing the tumor infiltration and activation of NK cells.乐伐替尼通过增强自然杀伤细胞的肿瘤浸润和激活来促进抗肿瘤免疫。
Am J Cancer Res. 2019 Jul 1;9(7):1382-1395. eCollection 2019.
8
Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment.仑伐替尼，一种具有广泛应用的分子：从临床前证据到抗癌治疗的未来发展
Cancer Manag Res. 2019 May 1;11:3847-3860. doi: 10.2147/CMAR.S188316. eCollection 2019.
9
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.转移性三阴性乳腺癌的免疫诱导策略，以提高对 PD-1 阻断的敏感性：TONIC 试验。
Nat Med. 2019 Jun;25(6):920-928. doi: 10.1038/s41591-019-0432-4. Epub 2019 May 13.
10
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.仑伐替尼联合帕博利珠单抗治疗晚期子宫内膜癌患者：一项多中心、开放标签、单臂、2 期临床试验的中期分析。
Lancet Oncol. 2019 May;20(5):711-718. doi: 10.1016/S1470-2045(19)30020-8. Epub 2019 Mar 25.